Overview
Real-World Experience in Diagnosing and Managing PNH in Special Patient Populations
Expert Commentary and Case Reviews
Click the "View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
In a “how I do it” clinical commentary, Dr. Jamile Shammo and Dr. Ilene Weitz share their real-world experience in the diagnosis and management of PNH in special patient populations. This case-based activity includes clinical scenarios and treatment strategies to improve patient outcomes.
This educational activity is designed for hematologists, oncologists, pediatricians, OB/GYNs, and the multidisciplinary healthcare team who are involved in the care of patients with PNH.
The purpose of this activity is to improve the identification and treatment of paroxysmal nocturnal hemoglobinuria through discussion of diagnostic recommendations, appropriate lab testing, and clinical trial evidence for therapeutic options within the context of patient cases.
Upon completion of this activity, participants will be able to:
• Discuss real-world experience in diagnosing and treating PNH in special patient populations
• Formulate personalized treatment strategies considerate of patient risks, characteristics, complications, and preferences
• Discuss coordination of care and clinical strategies amongst specialists to improve patient outcomes
• Discuss real-world experience in diagnosing and treating PNH in special patient populations
• Formulate personalized treatment strategies considerate of patient risks, characteristics, complications, and preferences
• Discuss coordination of care and clinical strategies amongst specialists to improve patient outcomes
Sponsored by Rush University Medical Center and the Academy for Continued Healthcare Learning (ACHL).
Supported by educational grants from Alexion Pharmaceuticals, Inc and Apellis Pharmaceutical, Inc.
Jamile Shammo, MD
Professor of Medicine and Pathology
Rush University Medical Center
Chicago, IL
Professor of Medicine and Pathology
Rush University Medical Center
Chicago, IL
Ilene Weitz, MD
Professor of Medicine
Jane Anne Nohl Division of Hematology
Keck School of Medicine
University of Southern California
Los Angeles, CA
Disclosure Policy:
As a provider of continuing education, Rush University Medical Center requires everyone who has the ability to control or influence the content of an educational activity to disclose information about all of their financial relationships with ineligible companies within the prior 24 months. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose regardless of their view of the relevance of the relationship to the education. Mechanisms are in place to identify and mitigate any potential conflicts of interest prior to the start of the activity.
As a provider of continuing education, Rush University Medical Center requires everyone who has the ability to control or influence the content of an educational activity to disclose information about all of their financial relationships with ineligible companies within the prior 24 months. There is no minimum financial threshold; individuals must disclose all financial relationships, regardless of the amount, with ineligible companies. Individuals must disclose regardless of their view of the relevance of the relationship to the education. Mechanisms are in place to identify and mitigate any potential conflicts of interest prior to the start of the activity.
The following financial relationships have been disclosed:
Ilene Weitz, MD
Sources of Funding for Research:
Consulting Agreements: Apellis Pharmaceutical, Inc., Norvartic, BioCryst Pharmaceuticals, Inc.
Speakers' Bureau: Alexion Pharmaceuticals, Inc
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Potential use of eculizumab, ravulizumab, and pegcetacoplan during pregnancy; investigational therapies for the treatment of PNH: ABP 959, SB12, BCD-148, crovalimab, SKY59, RO7112689, tesidolumab, LFG316, pozelimab, REGN3918, zilucoplan, RA101495, nomacopan, VA576, coversin, cemdisiran, ALN-CC5, danicopan, ACH-4471, BCX9930, iptacopan, LNP023
Jamile Shammo, MD
Sources of Funding for Research: Abbvie, Alexion Pharmaceuticals, Inc., AstraZeneca , Bristol Meyers Squibb, Incyte, CTI BioPharma, Kartos Therapeutics, Novartis, Stemline Therapeutics, Inc.,
Consulting Agreements: Alexion, Apellis Pharmaceutical, Inc., Bristol Meyers Squibb, Incyte, Novartis, Sanofi, Takeda
Stockholder: Abbvie, Baxter, Takeda
Speakers' Bureau: Alexion, Bristol Meyers Squibb, Incyte, Sanofi
Other: DSMC for Apellis, NS Pharma, Inc.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Potential use of eculizumab, ravulizumab, and pegcetacoplan during pregnancy; investigational therapies for the treatment of PNH: ABP 959, SB12, BCD-148, crovalimab, SKY59, RO7112689, tesidolumab, LFG316, pozelimab, REGN3918, zilucoplan, RA101495, nomacopan, VA576, coversin, cemdisiran, ALN-CC5, danicopan, ACH-4471, BCX9930, iptacopan, LNP023
ACHL and Rush University Medical Center staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
Unapproved Uses of Drugs/Devices: In accordance with requirements of the FDA, the audience is advised that information presented in this continuing medical education activity may contain references to unlabeled or unapproved uses of drugs or devices. Please refer to the FDA approved package insert for each drug/device for full prescribing/utilization information.
This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view this internet enduring activity and complete the posttest and evaluation. To receive credit, 60% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
In support of improving patient care, Rush University Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity is being presented without bias and with commercial support.
Rush University Medical Center designates this live activity for a maximum of one (1) AMA PRA Category 1 Credit™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
Rush University Medical Center designates this live activity for a maximum of one (1) nursing contact hour.
